^
Association details:
| Biomarker: | STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Microsatellite instability and mismatch repair deficiency define a distinct subset of lung cancers characterized by smoking exposure, high tumor mutational burden and recurrent somatic MLH1 inactivation.
Published date:
10/12/2023
Excerpt:
In NSCLC, STK11, KEAP1, and JAK1 were mutated in non-responders but wild type in responders.
DOI:
https://doi.org/10.1016/j.jtho.2023.10.004
Source:
Title:
STK11 and KEAP1 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)
Published date:
06/20/2022
Excerpt:
This retrospective study analyzed a cohort of Hispanic patients (N=103) diagnosed with mNSCLC from the US and seven Latin American countries (LATAM) treated with immune checkpoint inhibitors (ICI) alone or in combination...When we compared the cohorts A and B, OS was significantly shorter for patients carrying STK1 [STK11Mut 14.2 months versus STK11Wt 27.0 months (p=0.0001)] or KEAP1 [KEAP1Mut 12.0 months versus KEAP1Wt 24.4 months (p=0.005)] mutations.
DOI:
https://doi.org/10.1016/j.lungcan.2022.06.010
Source:
Title:
Genomic markers associated with hyperprogression in patients with lung cancer treated with immune checkpoint inhibitors.
Published date:
05/19/2021
Excerpt:
Pts with NSCLC treated with ICIs...98 of 427 pts (23%)had HP and an additional 86 pts (20%) had progressive disease...By tumor gene alterations, HP was seen in pts with: EGFR (20/60), STK11/LKB1 (16/25); and MDM2/4 (4/7).
DOI:
10.1200/JCO.2021.39.15_suppl.9105
Source:
Title:
The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and the influence of the NLR in NSCLC patients treated with immunotherapy. Add to Collection
Published date:
05/19/2021
Excerpt:
We conducted a retrospective study including all consenting patients with NSCLC treated with ICI...The presence of STK11 and/or KEAP1 mutations was associated with a negative impact on survival when compared with wild-type (median OS 7.4 vs 20.4 months, p = 0.001)....The STK11 and KEAP1 mutations are significant adverse predictors of ICI therapy benefit.
DOI:
10.1200/JCO.2021.39.15_suppl.e21010
Source:
Title:
107P - Immune Checkpoint Inhibitor (ICPI) resistance genes STK11 and KEAP1: A comparative Comprehensive Genomic Profiling (CGP) study
Published date:
09/14/2020
Excerpt:
NSCLC was the predominant disease type with both SK11mut (65%) and KEAP1mut (55%) cases....In addition, STK11mut and KEAP1mut tumors feature biomarkers predictive of ICPI benefit despite the likelihood of resistance and a paucity of targeted therapy opportunities.
Source:
Title:
STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
Published date:
09/03/2020
Excerpt:
Of 2407 patients with mNSCLC, STK11m and KRASm/STK11m were present in 13.6% and 6.5% of patients, respectively. Worse OS outcomes were observed in patients with STK11m versus STK11wt mNSCLC receiving IO...
DOI:
10.1371/journal.pone.0238358
Source:
Title:
Serine/threonine kinase 11 (STK11) mutations and immunotherapy resistance in patients with non-small cell lung cancer.
Published date:
05/13/2020
Excerpt:
...STK11 mut patients had an inferior PFS and OS…The presence of STK11 mut were associated with shorter OS/PFS in NSCLC pts treated with CPIs, proving its utility as a negative predictive marker.
DOI:
10.1200/JCO.2020.38.15_suppl.e15055
Source:
Title:
Genomic alterations profiling by liquid biopsy and their association to immune checkpoints inhibitors (ICI) response in a cohort of non-small cell lung cancer (NSCLC) patients.
Published date:
05/13/2020
Excerpt:
mPFS in patients harboring KRAS mutations was 4.9 m ( vs 10.1 m in patients without KRASmut, logrank test p-value = 0.031) and 4.1 m in those patients with STK11 mutations (vs 9.5 m in patients without STK11mut, logrank test p-value = 0.034). Additionally, mutations in both genes were also associated to statistically significant shorter mPFS 3.9 m vs 9.5 m (logrank test p-value < 0.01).
DOI:
10.1200/JCO.2020.38.15_suppl.e21524
Source:
Title:
Abstract 5668: Genomic correlates of PD-L1 expression are associated with response to immunotherapy in non-small cell lung cancer
Published date:
04/28/2020
Excerpt:
STK11 mutation (Log-rank test, q=0.1), EGFR mutation (q<1e-3), and CN loss of PD-L1, PD-L2, and/or JAK2 (q=0.02) were all significantly associated with worse PFS after ICB. EGFR mutation was significantly associated with worse OS after ICB (q=0.19).
DOI:
10.1158/1538-7445.AM2020-5668
Source:
Title:
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome
Excerpt:
STK11 mutated patients (n=9) showed a trend for worse OS only if treated with ICIs.
DOI:
10.21037/tlcr-20-674
Source:
Title:
Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer
Excerpt:
Forty-one patients with STK11-mutated NSCLC seen in our Thoracic oncology clinic with available next-generation sequencing tumor data were included in the analysis….In TCGA survival analysis, tumors with STK11 mutation with or without KRAS co-mutation were associated with worse survival (P<0.05)...
DOI:
10.21037/jtd-21-1377
